Novavax announced it has submitted the final round of data on its COVID-19 vaccine to the U.S. Food and Drug Administration (FDA) in anticipation of submitting a request to the agency for emergency use authorization (EUA) in a month. The final data is related to the vaccine’s manufacturing processes, and its submission is the final prerequisite

Leave a Reply